Physiomics to present on dual immuno-therapy at AACR 2020 Virtual Meeting II
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Academy of Cancer Research (“AACR”) Annual Meeting 2020, being held as a virtual event.
The Company will be presenting on a new version of its Virtual Tumour™ model, which is able to simulate the efficacy of dual immuno-therapy regimens. The model was originally developed as part of a client project.
The Company will be presenting an original poster in the session “LBPO.IM02 – Late-Breaking Research: Immunology 2”, scheduled for 22 June 2020 at 9.00 a.m. – 6.00 p.m. EDT (Eastern Daylight Time). The poster is titled “Optimising dual immuno-oncology combinations with Virtual Tumour” (Abstract # LB-392). The session will include live interactions and the poster will remain available for viewing by registered attendees for at least three months after the virtual meeting.
Over recent years, driven by a number of actual client projects, we have extended our Virtual Tumour™ technology from a tool to predict the effect of drugs directly targeting tumour growth inhibition, into one that can also simulate the effects of immuno-therapies. This latest release of the Virtual Tumour™ immune module can simulate the effects of established immune checkpoints (e.g. anti PD-(L)1) in combination with agents targeting components of the innate immune system, such as myeloid derived suppressor cells (e.g. complement inhibitors).
A copy of the poster will be made available on Physiomics’ website at 9.00 a.m. EDT (2.00 p.m. BST) at: https://www.physiomics.co.uk/wp-content/uploads/2020/06/PYCAACR2020_poster_final_LB_392.pdf.
According to AACR, it is the oldest and largest scientific organisation in the world, focused on every aspect of high-quality, innovative cancer research. Its annual conference is usually attended by representatives from public and private sector organisations, from the very small to the largest global players, with over 20,000 participants attending in 2019. This year, as a virtual event, access will be free to everyone who registers, and presentations may therefore reach a wider audience than usual.
More information about the conference may be found using the following link: https://www.aacr.org/meeting/aacr-annual-meeting-2020.
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.